user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 449112 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

Sellers Reduce Exposure to Shares of NPS Pharmaceuticals on 1.2x Above-Average Volume (NPSP)

Published on Tue, 02/26/2013 - 14:17
By Robert Cotter

The price of NPS Pharmaceuticals shares has slipped to $7.48 (a 0.8% change) on heavy trading volume. Approximately 1.6 million shares have changed hands today vs. average 30-day volume of 1.3 million shares. Spikes in volume can validate a breakout or signify a potential turning point.

NPS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.

Over the past year, NPS Pharmaceuticals has traded in a range of $6.30 to $11.22 and is now at $7.48, 19% above that low. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 1.3%.

NPS Pharmaceuticals (NASDAQ:NPSP) has potential upside of 120.0% based on a current price of $7.48 and analysts' consensus price target of $16.45. The stock should run into initial resistance at its 200-day moving average (MA) of $8.55 and subsequent resistance at its 50-day MA of $8.83.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

TD Securities Made the Right Call, Pan A...

Pan American Silver was downgraded from Buy to Hold by TD Securities one week ago. The ...

Analyst Rating In Review: Medivation Bid...

One week ago Medivation (NASDAQ:MDVN) was downgraded from Buy to Neutral at Goldman Sac ...

Auxilium Pharmaceuticals In Retrospect: ...

RBC Capital downgraded Auxilium Pharmaceuticals (NASDAQ:AUXL) from Outperform to Sector ...

Analyst Rating In Review: Marvell Techno...

A week ago, JMP Securities upgraded Marvell Technology from Underperform to Market Perf ...

Buffalo Wild Wings Fulfills the Promise:...

A week ago, Miller Tabak upgraded Buffalo Wild Wings from Hold to Buy. Buffalo Wild Wi ...

Ericsson Down 1.6% Since UBS Downgraded ...

UBS downgraded Ericsson (NASDAQ:ERIC) from Buy to Neutral a week ago. The shares close ...

Analyst Rating Flashback: SYNNEX Up 8.1%...

Raymond James upgraded SYNNEX (NYSE:SNX) from Market Perform to Outperform a week ago. ...

Freeport-McMoRan In Retrospect: Shares D...

A week ago, Tigress Financial downgraded Freeport-McMoRan from Strong Buy to Neutral. ...